Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $124
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $86 to $124.
Wells Fargo analyst Derek Archila maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $86 to $124.